GT Biopharma
GTBPPhase 2Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.
Market Cap
$14.5M
Focus
AntibodiesBiologicsSmall Molecules
GTBP · Stock Price
USD 0.4686.84 (-99.47%)
Historical price data
About
Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.
Pipeline Snapshot
11 drug in pipeline
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | High-risk Myelodysplastic Syndromes | Phase 1/2 |
Funding History
2Total raised: $15M
PIPE$10MUndisclosedAug 15, 2022
PIPE$5MUndisclosedFeb 15, 2021
Company Info
TypePublic
LocationUnited States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile